A Dynamic Time at ASH 2015

| Hugh Schaffer

This has been an experience beyond my imagination. The fact that the International Myeloma Foundation (IMF) extended an invitation to attend this year’s American Society of Hematology (ASH) Conference in Orlando, Florida, was humbling. I approached this project with anxiety, wondering if I could relay an accurate impression for those who would be reading my […]

All Good Things Must Come to an End

| Anne Pacowta

All good things must come to an end, as they did this Monday evening for the fifteen Support Group Leaders (SGLs) who attended American Society of Hematology (ASH) conference this year. For many, it was not the first time at ASH; however, there were two, as we call them, newbies. But as the weekend progressed, […]

New Pathways and Approaches for MM Treatment

| Jim Omel

At ASH, I always look for new ideas and approaches for treating myeloma.  What is new?  What is coming, and what is close to being clinically useful for patients?  Every drug has its start in pre-clinical testing (cell lines), moves on to animal testing, and then makes the move to phase I safety and dosage […]

More Answers or More Questions?

| Teresa Miceli

As the 57th Annual Meeting and Exposition of the American Society of Hematology (ASH) comes to an end, I come to the overwhelming sense that I may now have more questions than answers. Yes, we have had a “November to Remember” with three new drugs receiving Food and Drug Administration (FDA) approval for treating relapsed […]

My First Day at ASH 2015

| Carlene Pratt

On the first day at ASH 2015, all the other Support Group Leaders and I walked into the Hyatt Regency Orlando. Immediately, I noticed the Christmas trees decorated nicely and the smell of poinsettias. We were able to gather around the Christmas trees and take a group picture. After seeing the diverse crowds of people walking in every direction […]


| Jack Aiello

Before presenting my ASH summary, I’ll mention a late-breaking abstract presentation that I attended this morning.  Maybe you’ve already heard about CAR-T therapy (Chimeric Antigen Receptor for T-cells).  This very new immunology treatment removes T-cells from the patient and re-engineers and re-infuses them in the patient, so that these CAR-T cells recognize and destroy cancer […]

From the sidelines of the IMWG breakfast and the Cancer Research Center of Spain’s presentation

| Hugh Schaffer

Today was an exciting day for me!  The pleasure of being invited to the International Myeloma Working Group (IMWG) breakfast and hearing Dr. Durie’s Highlights of his American Society of Hematology (ASH) presentation added to the excitement. I was impressed by the congeniality of these men and women as several others shared highlights of their […]

Day 3 at ASH 2015

| Jack Aiello

Today was the final full day of ASH, and I attended oral presentations this morning beginning at 7 a.m.  With all the excitement about recent multiple myeloma drug approvals last month, I wondered what might be next.  The answer might be a drug called Pembrolizumab (Pembro), an anti PD-1 antibody that is also referred to […]

Getting Closer to CURE . . . Minimal Residual Disease (MRD)

| Jim Omel

Myeloma treatment has changed dramatically since my diagnosis 18 years ago. Prior to 2000, complete response (CR) used to be defined as a 75% reduction in M-protein, and stringent complete response (sCR) was a non-issue because it just didn’t happen. Now, however, therapies often take us beyond sCR to amazingly low levels of only one […]

New Approvals – Now What?

| Linda Huguelet

The American Society of Hematology (ASH) Conference and Exhibition is filled with much excitement and buzz about the approval of two monoclonal antibodies Darzalex (daratumumab)and Empliciti (elotuzumab). Monoclonal antibodies are a class of drugs that we’ve all been eagerly awaiting – the Exhibit Hall is splashed with large images of “Now Approved,” and “It’s here.” […]